Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Fatal Familial Insomnia Seen by the Smallest Number of Doctors: SSRI, M3 Survey
September 6, 2010
- Generics Use Rate Up 0.9 Points to 18.9% on Volume Basis in FY2009
September 6, 2010
- Takepron Approved for Prevention of NSAID-Associated Ulcers
September 6, 2010
- Carna Biosciences Embarks on Contract Drug Discovery Business
September 6, 2010
- Merck Serono to Enter CNS Field by Launching Cladribine by 2014
September 6, 2010
- ImmuCyst Approved for Adjuvant Therapy after TURBT
September 6, 2010
- Tella Ties Up with Jikei University for Vaccine Therapy
September 6, 2010
- Sanofi-aventis to Take Over Genzyme
September 6, 2010
- Revlimid Approved for Myelodysplastic Syndrome
September 6, 2010
- JPMA's Biopharmaceutical Committee Gears Up Activities
September 6, 2010
- Novartis Licenses Rabies Vaccine to Kaketsuken
September 6, 2010
- Precedex Approved for Long-Term Administration of over 24 Hours
September 6, 2010
- Takara Bio Begins Clinical Research for TCR Gene Therapy
September 6, 2010
- Genzyme Licenses Synvisc to Teijin Pharma
September 6, 2010
- Denosumab Applied for Bone Metastases: Daiichi Sankyo
September 6, 2010
- Pola to Comarket Teika's Bedsore Treatment Sorenurse
August 30, 2010
- Nippon Chemiphar: Generics Account for 64% of Total Sales
August 30, 2010
- PMDA Calls For Regular Lab Tests in Patients Treated with SASP
August 30, 2010
- R-Tech Ueno Terminates Licensing Agreement for Human Serum Albumin with MTPC
August 30, 2010
- Fuji Pharma: Generic Diagnostics Drive Business
August 30, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…